Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus

Sponsor
Mashhad University of Medical Sciences (Other)
Overall Status
Unknown status
CT.gov ID
NCT01375101
Collaborator
(none)
30
1
2
17
1.8

Study Details

Study Description

Brief Summary

Lichen planus (LP) is a common chronic inflammatory mucocutaneous disease with an immunologic etiology ,which has number of different clinical forms. Alternative natural or herbal origine drugs with antioxidant and anti-inflammatory properties have been used individually or in combination with systemic corticosteroids in order to decrease adverse drug reactions.

This study was conducted to evaluate the effect of quercetin on treatment of erosive -atrophic lesions of oral lichen planus (OLP).

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Study Start Date :
Apr 1, 2010
Anticipated Primary Completion Date :
Sep 1, 2011
Anticipated Study Completion Date :
Sep 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: quercetin

quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action

Drug: Quercetin
The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth

Placebo Comparator: placebo

placebo capsul is produced with lactose for using in placebo/ control group.

Drug: placebo
The patient is directed to use placebo capsule two times a day, ,until the one mouth

Outcome Measures

Primary Outcome Measures

  1. the effects of this Drug on OLP measured with VAS scale for pain and evaluation of intensity of lesions. [2 months]

    In the present work the Analogical Visual Scale is used TO evaluate pain,and we also record the intensity of lesions weekly and any side effect of this Drug

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • confirmation of clinical diagnosis of Atrophic and erosive lichen planus by histological examination

  • two weeks wash out periods after the last treatment

  • having the experience of atrophic and erosive lesion greater than 1 cm having the experience of pain and burning greater than 3.5 in VAS Score

Exclusion Criteria:
  • confirmation of dysplasia and malignancy in histologic examination

  • confirmation of lichenoid reaction in histologic examination

  • pregnancy and breast feeding

  • using fluorokinolon and cyclosporin which interact with quercetin

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mashhad university of Medical science, Research Center of oral and maxillofacial medicine Mashhad Khorasan Razavi Iran, Islamic Republic of 91735

Sponsors and Collaborators

  • Mashhad University of Medical Sciences

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01375101
Other Study ID Numbers:
  • 88705
First Posted:
Jun 17, 2011
Last Update Posted:
Jul 26, 2011
Last Verified:
Jul 1, 2011
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 26, 2011